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Several molecular subtypes of sporadic Creutzfeldt–Jakob disease have been identiﬁed and electroencephalogram and cere-
brospinal ﬂuid biomarkers have been reported to support clinical diagnosis but with variable utility according to subtype.
In recent years, a series of publications have demonstrated a potentially important role for magnetic resonance imaging in
the pre-mortem diagnosis of sporadic Creutzfeldt–Jakob disease. Magnetic resonance imaging signal alterations correlate with
distinct sporadic Creutzfeldt–Jakob disease molecular subtypes and thus might contribute to the earlier identiﬁcation of the
whole spectrum of sporadic Creutzfeldt–Jakob disease cases. This multi-centre international study aimed to provide a rationale
for the amendment of the clinical diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Patients with sporadic Creutzfeldt–
Jakob disease and ﬂuid attenuated inversion recovery or diffusion-weight imaging were recruited from 12 countries. Patients
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analysed as controls. All magnetic resonance imaging scans were assessed for signal changes according to a standard protocol
encompassing seven cortical regions, basal ganglia, thalamus and cerebellum. Magnetic resonance imaging scans were eval-
uated in 436 sporadic Creutzfeldt–Jakob disease patients and 141 controls. The pattern of high signal intensity with the best
sensitivity and speciﬁcity in the differential diagnosis of sporadic Creutzfeldt–Jakob disease was identiﬁed. The optimum
diagnostic accuracy in the differential diagnosis of rapid progressive dementia was obtained when either at least two cortical
regions (temporal, parietal or occipital) or both caudate nucleus and putamen displayed a high signal in ﬂuid attenuated
inversion recovery or diffusion-weight imaging magnetic resonance imaging. Based on our analyses, magnetic resonance
imaging was positive in 83% of cases. In all deﬁnite cases, the amended criteria would cover the vast majority of suspected
cases, being positive in 98%. Cerebral cortical signal increase and high signal in caudate nucleus and putamen on ﬂuid
attenuated inversion recovery or diffusion-weight imaging magnetic resonance imaging are useful in the diagnosis of sporadic
Creutzfeldt–Jakob disease. We propose an amendment to the clinical diagnostic criteria for sporadic Creutzfeldt–Jakob disease
to include ﬁndings from magnetic resonance imaging scans.
Keywords: CJD; MRI; FLAIR; DWI; molecular subtypes; dementia
Abbreviations: CSF=cerebrospinal ﬂuid; DWI=diffusion-weight imaging; EEG=electroencephalography; FLAIR=ﬂuid attenuated
inversion recovery; IgG=immunglobulin G; MRI=magnetic resonance imaging; sCJD=sporadic Creutzfeldt–Jakob disease;
PRNP=prionprotein gene; PrPSc=pathogenic Prion protein; SREAT=steroid responsive encephalitis associated with autoimmune
thyroiditis
Introduction
Sporadic CJD (sCJD) is a transmissible neurodegenerative disorder
with a fatal outcome. Clinical diagnostic criteria for sCJD were ﬁrst
formulated 30 years ago, using a combination of distinctive clinical
features and best available auxiliary paraclinical investigations,
which at that time was electroencephalography (EEG) (Masters
et al., 1979). In recent years, there has been progress in develop-
ing other specialist investigations, including useful surrogate
biomarkers in the cerebrospinal ﬂuid (CSF), and clinical diagnostic
criteria have been amended (Zerr et al., 2000a; Collins et al.,
2006).
A series of recent publications has dealt with the clinical and
pathological phenotypes and heterogeneity in sCJD (Parchi et al.,
1999; Gambetti et al., 2003; Castellani et al., 2004; Collins et al.,
2006; Sanchez-Juan et al., 2006). It has become apparent that
a multimodal approach may be necessary if detection of the
entire phenotypic spectrum of sCJD is to be achieved (Zerr
et al., 2000b). Whereas some classical molecular subtypes such
as the MM1 subtype frequently display periodic sharp and slow
wave complexes in the EEG, the other ﬁve molecular subtypes are
negative with this investigation (Parchi et al., 1999; Castellani et al.,
2004; Collins et al., 2006). Utilizing CSF 14-3-3 protein detection
provides a higher sensitivity, including less typical subtypes of sCJD
such as VV1 and VV2 subtypes (Collins et al., 2006; Sanchez-Juan
et al., 2006; Geschwind et al., 2009). However, even for CSF 14-3-
3 protein detection with an overall sensitivity of 85%–95%,
biological variables modify the test results and cases with longer
duration or younger age at onset may be missed by this investiga-
tion (Castellani et al., 2004; Sanchez-Juan et al., 2006).
Acknowledging the limitations of the clinical criteria, the search
for additional sCJD diagnostic investigations has continued.
Magnetic resonance imaging (MRI) has become increasingly
important in the clinical diagnosis of sCJD. The use of sensitive
ﬂuid attenuated inversion recovery (FLAIR) and diffusion-weight
imaging (DWI) sequences allows the detection of basal ganglia
hyperintensity and signal increase in other brain regions (Satoh
et al., 2007; Tschampa et al., 2007; Fujita et al., 2008;
Galanaud et al., 2008; Meissner et al., 2008). Characteristic MRI
lesion patterns corresponding to individual CJD subtypes have
been reported (Meissner et al., 2009). As MRI ﬁndings, even
from early in the illness, are proving valuable in the evaluation
of suspected sCJD patients, both by excluding other disorders
and by demonstrating features considered typical of human
prion disease (Geschwind et al., 2009), we undertook a systematic
multi-centre international collaborative study to analyse the value
of MRI lesion patterns in comparison to CSF biomarker 14-3-3 and
periodic sharp wave complexes in the EEG in terms of test sensi-
tivity and speciﬁcity.
Material and Methods
Patients
Cases were included from twelve countries (Argentina, Australia,
Belgium, Canada, France, Germany, Italy, Netherlands, Portugal,
Slovenia, Switzerland and United Kingdom) according to the following
criteria: (i) CJD diagnosis conﬁrmed by brain pathology (deﬁnite
cases) or fulﬁlling accepted case deﬁnition criteria for ‘probable’ sCJD
(data used for a separate set of analyses); (ii) molecular subtype deter-
mined by codon 129 genotyping (MM, MV or VV) and western blot
analysis of brain pathogenic prion protein (PrPSc) type (1 or 2) (corre-
sponding to MM1, MM2, MV1, MV2, VV1 and VV2 subtype) (Parchi
et al., 1996, 1999); and (iii) available FLAIR or DWI MRI of the brain.
Controls
Controls were included according to the following criteria: (i) cases in
which the diagnosis of sCJD was suspected (patients classiﬁed at least as
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gations (improvement or recovery, inﬂammatory CSF ﬁndings, other
diagnosis) or at autopsy; and (ii) available FLAIR or DWI brain MRI.
Codon 129 status was determined either as part of genotyping of
the entire prion protein gene (PRNP) open reading frame or by restric-
tion fragment length polymorphism analysis (Collins et al., 2006).
Genetic CJD (causal mutations found in prionprotein gene), iatrogenic
and variant CJD cases were excluded.
EEG (periodic sharp wave complexes) ﬁndings were also ascertained.
The CSF 14-3-3 immunoassays were performed using western blotting
as previously reported (Zerr et al., 2000a) and the conformity of test
methods and interpretation of results was conﬁrmed by a blinded
sample exchange programme between laboratories (Sanchez-Juan
et al., 2006).
The study comprised 436 sCJD patients who died between April
1998 and March 2007, and 141 controls: 32 (5.5%) from
Argentina, 15 (2.6%) from Australia, 35 (6.1%) from Belgium,
9 (1.6%) from Canada, 16 (2.8%) from France, 328 (56.8%) from
Germany, 32 (5.5%) from Italy, 17 (2.9%) from Netherlands,
7 (1.2%) from Portugal, 4 (0.7%) from Slovenia, 7 (1.2%) from
Switzerland and 75 (13.0%) from UK.
MRI data
The magnetic resonance images were performed as routine clinical
diagnostic studies and were collected from various hospitals in the
framework of epidemiological studies as reported elsewhere
(Meissner et al., 2009).
The majority of the scans were available as hardcopy. If serial MRIs
were available, the ﬁrst examination was used for the analysis. All
scans were assessed by at least one neuroradiologist (K.K., D.S.,
C.R., P.S. or D.C.) aware that sCJD was a differential diagnostic possi-
bility but blinded to the ﬁnal diagnosis. All neuroradiologists assessed a
small MRI series for the estimation of the inter-observer agreement.
The intra reader concordance was high: 93.3%, =0.64 (P50.001).
Inter-rater concordance was 89%, =0.61 (P50.001) and 82%,
=0.62 (P50.001) (which is high agreement) or 75.4%, =0.50
(P50.001) and 76%, =0.45 (P50.001) (moderate agreement).
A standardized protocol was used which included seven cerebral
cortex regions (speciﬁcally the cingulate gyri, insular regions and
hippocampi, as well as the remaining frontal, parietal and temporal
lobes and the occipital lobes), basal ganglia (caudate nucleus, puta-
men, globus pallidus), thalamus (anterolateral nuclei, mediodorsal
nuclei, pulvinar) and cerebellar cortex. For the thalamus, the presence
or absence of a ‘pulvinar sign’ with extension into the antero-medial
thalamus underscoring the ‘hockey stick sign’ was also rated
(hyperintensity of the pulvinar relative to the anterior putamen)
(Collie et al., 2003). The cerebral regions were assessed as hyperin-
tense in relation to isointense cortex areas. As most MRI data were
available as hardcopy only, the grade of hyper-intensity was not
quantiﬁed. For each MRI examination, T2-weighted (T2-w) images
were evaluated ﬁrst, followed by FLAIR and DWI. For further analyses,
only FLAIR and DWI were considered e.g. only the most sensitive
sequences, FLAIR and DWI (Kallenberg et al., 2006), were considered.
Proton-density-weighted scans and apparent diffusion coefﬁcient maps
were less commonly used and not included in this study. Areas of
hyperintensity were scored separately for each sequence. The quality
of the complete MRI examination was graded from 1 to 6 (1=excel-
lent, 2=good, 3=average, 4=sufﬁcient, 5=insufﬁcient, 6=poor).
Scans graded higher than 4 were considered as non-diagnostic
(mainly due to motion artefacts) and excluded from the study.
Statistical analysis
Descriptive statistics were reported for sCJD and control patients;

2-test and the non-parametric Mann–Whitney test were used to
assess differences between categorical and continuous variables.
The goal of our study was to identify the best combination of radi-
ological ﬁndings and MRI sequences to discriminate between sCJD and
non-sCJD patients. In order to do this we compared the results of
visual assessments of brain MRI scans in cases and controls. We con-
sidered a brain region as affected when a high signal was found in
either FLAIR or DWI MRI sequences. We calculated sensitivity
[the percentage of scans considered as characteristic (positive) of
sCJD in cases] and speciﬁcity [the percentage of scans considered as
not characteristic (negative) of sCJD in controls] for several criteria
patterns involving different combinations of affected regions and
MRI sequences. We also calculated diagnostic odds ratios—the ratio
of the odds of positivity in sCJD cases relative to the odds of positivity
in the controls—to assess which combinations of criteria patterns
yielded better test discriminatory performance; 95% conﬁdence inter-
vals of the diagnostic odds ratios were estimated by the exact method.
Inter-reader agreement for brain MRI scan visual assessment
(normal or affected) was calculated, using Cohen’s  coefﬁcient and
Concordance Index, for all explored areas included in the standardized
protocol. Concordance Index is the percentage of agreement between
readers and the  coefﬁcient shows the difference in agreement, from
chance, between them; thus a -value of 0 means no different from
chance and 1 is perfect agreement.
Ethics
The study was done in accordance with the current revision of the
Declaration of Helsinki and the Good Clinical Practice: Consolidated
Guideline approved by the International Conference on Harmonization
and applicable to national and local laws and regulations. For each
participating site, the study protocol and all amendments were
approved by an institutional review board or independent ethics
committee. All patients and their caregivers gave written informed
consent.
Results
Patients
In total, MRI scans were available for 436 patients with sCJD and
141 controls.
FLAIR sequences were available in 379 cases and in 128 controls,
DWI in 258 cases and 81 controls. Both sequences were available
in 201 cases and 68 controls. The median time from onset to
MRI was 2.7 months in sCJD cases and 6.7 months in controls.
Patient characteristics are summarized in Table 1.
Deﬁnition of the criteria
In the ﬁrst part of the study, we analysed which FLAIR and/or
DWI MRI lesion pattern was characteristic for sCJD, regardless of
molecular subtype. To achieve this, a stepwise analysis was
performed: (i) selection of the cortical regions; (ii) combination
cortical/subcortical areas; and (iii) deﬁnition of the best MRI
sequence (FLAIR/DWI).
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In this part of the study, we analysed the frequency of high signal
detection in each cortical region for cases and controls and strati-
ﬁed the data by the MRI technique used (FLAIR or DWI, Table 2).
As the result of this analysis, we selected three regions with the
optimum sensitivity and speciﬁcity data, irrespective of MRI tech-
nique used. The three areas with the highest values for diagnostic
accuracy were the parietal, occipital and temporal cortical regions.
The other cortical brain regions such as cingulate gyrus, insular
cortex or hippocampus were either non-discriminatory between
cases and controls, had low speciﬁcity and, in addition to this,
found low inter reader agreement, as reported before
(Krasnianski et al., 2008).
Combination of cortical and subcortical
areas
Various combinations of high signal intensity were analysed in
the three selected cortical (parietal, occipital and temporal) and
subcortical regions. The results are given in Table 3. For FLAIR
and DWI, the best results were obtained when two or more
regions (either temporal, parietal, occipital) displayed a high
signal in the MRI. The poorest speciﬁcity was obtained when
MRI scans were considered positive when only one or more cere-
bral cortical region showed a high signal; therefore, those patterns
were excluded for further analysis. For subcortical areas, the opti-
mum diagnostic accuracy was obtained when a high signal
increase was observed in both the caudate nucleus and putamen
simultaneously. DWI was generally more sensitive than FLAIR with
a similar speciﬁcity for both sequences.
Further analyses determined the best possible combination of
various cerebral cortical and subcortical high signal changes.
The highest diagnostic accuracy was obtained by accepting
either a combination of at least two cerebral cortical regions
(temporal, occipital, parietal) showing increased signal or both
the putamen and the caudate nucleus showing high signal inten-
sity (Table 4).
Deﬁnition of the MRI sequence
After choosing the combination of either at least two cerebral
cortical regions or both the putamen and caudate nucleus showing
high signal as the optimal radiological pattern, we analysed which
MRI pulse sequence or potential combination of sequences
revealed the highest sensitivity and speciﬁcity. Both sequences
achieved high diagnostic accuracy (Table 5). We calculated the
data for other potential combinations, such as FLAIR and DWI
positive, but the sensitivity achieved was only 54%.
In order to estimate the sensitivity and speciﬁcity of the combi-
nation FLAIR or DWI, we considered that patients with both pulse
sequences available were most reliable, because including patients
with only one sequence would result in a predominance of the
‘only FLAIR performed’ and a decrease in the sensitivity (Table 5),
since FLAIR is less sensitive than DWI.
False-positive ﬁndings in the MRI
According to our criteria, 19 controls had positive ﬁndings on the
MRI. Most of these suffered from an infectious or inﬂammatory
disorder of the central nervous system (n=9), like lymphocytic
encephalitis, progressive multifocal leucencephalopathy, steroid
responsive encephalitis associated with autoimmune thyroiditis
(SREAT) or encephalitis of unknown origin. In other patients
with a positive MRI, autopsy conﬁrmed Alzheimer’s disease
(n=2), Dementia with Lewy bodies (n=2), epilepsy (n=2),
intravascular lymphomatosis and mitochondrial cytopathy.
Table 1 Patient characteristics
n Autopsy
(%)
Female
(gender)
(%)
Median age
(range)
Median duration
(range) (months)
Time to
MRI
(months)
Codon
129 MM
n (%)
Codon
129 MV
n (%)
Codon
129 VV
n (%)
FLAIR
MRI (n)
DWI
MRI (n)
sCJD 436 60.3 55.6 64.0 (35.3–85.0) 6.4 (1.0–56.3) 2.7 195 (62.7) 58 (18.6) 58 (18.6) 379 258
controls 144 39.1 48.8 65.9 (25.9–91.5) 12.0 (0.0–104.0) 6.7 11 (44.0) 8 (32.0) 6 (24.0) 128 81
P-value 0.27 0.2 0.007
Table 2 Selection of cortical areas
Frontal Cinguli Parietal Temporal Occipital Insula Hippocampus
CJD (% positive) FLAIR 48 52 37 32 17 24 20
Control (% negative) FLAIR 75 71 89 82 97 89 76
CJD (% positive) DWI 74 71 65 59 37 52 21
Control (% negative) DWI 65 61 89 81 90 77 88
Diagnostic odds
ratio (95% CI)
FLAIR 2.73
(1.52–3.94)
2.636
(1.51–3.76)
4.986
(2.03–7.94)
2.058
(1.04–3.07)
6.43
(0.2–13.06)
2.382
(0.98–3.78)
0.77
(0.4–1.15)
DWI 5.21
(2.44–7.98)
3.667
(1.76–5.57)
14.7
(3.85–25.56)
5.92
(2.37–9.46)
5.48
(1.25–9.71)
3.58
(1.55–5.62)
1.89
(0.5–3.28)
CI=conﬁdence interval.
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distinctive MRI pattern could be detected for each disorder and
the frequency of high signal abnormalities in cortical and sub-
cortical areas was similar in all the diagnostic groups mentioned
above.
Modiﬁcation of clinical criteria for
sCJD
Based on our results, we recommend modifying the current clinical
diagnostic criteria for sCJD to include the detection of either
Table 3 Selection of cortical and subcortical areas
FLAIR DWI
Controls Total
sCJD cases
Deﬁnite
CJD cases
Controls Total
sCJD cases
Deﬁnite
sCJD cases
At least one cortical region
a affected
No (%) 94 (73.4) 190 (50.1) 111 (48.1) 60 (74.1) 57 (22.1) 29 (19.1)
Yes (%) 34 (26.6) 189 (49.9) 120 (51.9) 21 (25.9) 201 (77.9) 123 (80.9)
Diagnostic odds ratio (95% CI) 2.8 (1.5–4.0) 3.0 (1.6–4.4) 10.1 (4.3–15.9) 12.1 (4.4–19.9)
At least two cortical regions
a affected
No (%) 121 (94.5) 278 (73.4) 173 (74.9) 72 (88.9) 115 (44.6) 62 (40.8)
Yes (%) 7 (5.5) 101 (26.6) 58 (25.1) 9 (11.1) 143 (55.4) 90 (59.2)
Diagnostic odds ratio (95% CI) 6.3 (1.3–11.3) 5.8 (1.1–10.5) 10.0 (2.6–17.3) 11.6 (2.7–20.5)
More than three cortical regions affected
No (%) 115 (89.8) 276 (72.8) 163 (70.6) 68 (84.0) 111 (43.0) 57 (37.5)
Yes (%) 13 (10.2) 103 (27.2) 68 (29.4) 13 (16.0) 147 (57.0) 95 (62.5)
Diagnostic odds ratio (95% CI) 3.3 (1.3–5.3) 3.7 (1.3–6.1) 6.9 (2.5–11.4) 8.7 (2.8–14.6)
Putamen or caudatum affected
No (%) 104 (81.3) 147 (38.8) 83 (35.9) 67 (82.7) 83 (32.2) 44 (28.9)
Yes (%) 24 (18.8) 232 (61.2) 148 (64.1) 14 (17.3) 175 (67.8) 108 (71.1)
Diagnostic odds ratio (95% CI) 6.8 (3.5–10.2) 7.7 (3.7–11.7) 10.1 (3.7–16.5) 11.8 (3.8–19.7)
Both putamen and caudatum affected
No (%) 120 (93.8) 223 (58.8) 135 (58.4) 76 (93.8) 133 (51.6) 76 (50.0)
Yes (%) 8 (6.3) 156 (41.2) 96 (41.6) 5 (6.2) 125 (48.4) 76 (50.0)
Diagnostic odds ratio (95% CI) 10.5 (2.7–18.3) 10.7 (2.5–18.8) 14.3 (0.9–27.7) 15.2 (0.6–29.8)
a Parietal–temporal–occipital; CI=conﬁdence interval; s=sCJD cases.
Table 4 Selection of cortical and subcortical areas best combination
FLAIR DWI
Controls Total
sCJD cases
Deﬁnite
sCJD cases
Controls Total
sCJD cases
Deﬁnite
sCJD cases
More than three cortical regions OR both Put. and NC affected
No (%) 110 (85.9) 166 (43.8) 94 (40.7) 66 (81.5) 62 (24.0) 32 (21.1)
Yes (%) 18 (14.1) 213 (56.2) 137 (59.3) 15 (18.5) 196 (76.0) 120 (78.9)
Diagnostic odds ratio (95% CI) 7.8 (3.6–12.1) 8.9 (3.9–13.9) 13.9 (5.2-22.7) 16.5 (5.2-27.8)
More than three cortical regions OR Put. OR NC affected
No (%) 99 (77.3) 113 (29.8) 60 (26.0) 61 (75.3) 41 (15.9) 19 (12.5)
Yes (%) 29 (22.7) 266 (70.2) 171 (74.0) 20 (24.7) 217 (84.1) 133 (87.5)
Diagnostic odds ratio (95% CI) 8.0 (4.3–11.8) 9.7 (4.8–14.7) 16.1 (6.4–25.9) 21.4 (6.5–36.2)
At least two cortical regions
a affected OR both Put. and NC affected
No (%) 116 (90.6) 162 (42.7) 97 (42.0) 70 (86.4) 63 (24.4) 33 (21.7)
Yes (%) 12 (9.4) 217 (57.3) 134 (58.0) 11 (13.6) 195 (75.6) 119 (78.3)
Diagnostic odds ratio (95% CI) 13.0 (4.8–21.1) 13.4 (4.7–22.0) 19.7 (6.0–33.4) 23.0 (5.9–40.0)
At least two cortical regions
a affected OR Put. OR NC affected
No (%) 103 (80.5) 106 (28.0) 58 (25.1) 62 (76.5) 42 (16.3) 21 (13.8)
Yes (%) 25 (19.5) 273 (72.0) 173 (74.9) 19 (23.5) 216 (83.7) 131 (86.2)
Diagnostic odds ratio (95% CI) 10.6 (5.4–15.8) 12.3 (5.8–18.8) 16.8 (6.5–27.0) 20.4 (6.3–34.4)
NC=nucleus caudatum; Put.=putamen.
a Parietal–temporal–occipital.
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putamen) or in at least two cortical regions (from either the
temporal, parietal or occipital cerebral cortices) (Fig. 1). This
implies that the detection of the speciﬁed high signal abnormalities
in FLAIR or DWI MRI will be considered at the same level of
diagnostic importance as periodic sharp wave complexes on the
EEG or 14-3-3 protein detection in the CSF.
Comparative analysis of the EEG,
CSF and MRI
In a subgroup of 214 deﬁnite CJD patients and 77 deﬁnite
non-cases, we analysed the frequency of true-positive results in
cases (sensitivity) and true-negative results in controls (speciﬁcity),
in relation to the detection of periodic sharp wave complexes in
the EEG, elevated CSF levels of 14-3-3 protein or MRI abnormal-
ities. Diagnostic MRI abnormalities for sCJD, as deﬁned by our
analyses, were observed in 83% of such patients with a speciﬁcity
of 83%. For CSF 14-3-3 protein detection, test sensitivity was
86% but speciﬁcity was 68%. EEG had the lowest sensitivity
(44%) and highest speciﬁcity (92%). Details on comparative
analyses of current and amended criteria are given in Table 6.
The sensitivity of current criteria is 92%, the speciﬁcity 71%.
Thus, 8% of sCJD patients are not covered by the World Health
Figure 1 MRI-CJD Consortium criteria for sporadic Creutzfeldt–Jakob disease.
Table 5 Deﬁnition of MRI sequences for the pattern at
least two cortical regions affected (parietal–temporal–
occipital) or both putamen and nucleus caudatum affected
Controls Total
sCJD
cases
Deﬁnite
sCJD
cases
FLAIR AND DWI
No (%) 64 (94.1) 92 (45.8) 55 (45.8)
Yes (%) 4 (5.9) 109 (54.2) 65 (54.2)
Total (n) 68 201 120
Diagnostic odds
ratio (95%CI)
19.0 (0.9–38.8) 18.9 (1.4–39.2)
FLAIR OR DWI
No (%) 122 (86.5) 133 (30.5) 75 (28.5)
Yes (%) 19 (13.5) 303 (69.5) 188 (71.5)
Total (n) 141 436 263
Diagnostic odds
ratio (95%CI)
14.6 (7.0–22.3) 16.1 (7.2–25.0)
FLAIR OR DWI
a
No (%) 56 (82.3) 38 (18.9) 21 (17.5)
Yes (%) 12 (17.6) 163 (81.1) 99 (82.5)
Total (n) 68 201 120
Diagnostic odds
ratio (95%CI)
20.0 (5.7–34.4) 22.0 (4.8–39.2)
a Only cases with both sequences available.
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parameter for ‘probable’ CJD, the sensitivity of clinical criteria
rises substantially to 98%, but speciﬁcity drops marginally.
Value of MRI in identiﬁcation of
various molecular sCJD subtypes
A comparative analysis of protein 14-3-3, EEG and MRI in a
subset of CJD patients with data on pathogenic prion protein
type and codon 129 genotype available is shown in Table 7.
Currently used criteria improved the recognition of some of the
less typical sCJD subtypes such as VV2. Amended criteria, as
suggested here, are especially helpful for the rare and atypical
subtypes such as MM2, MV1 and MV2. The latter may develop
an atypical clinical syndrome and thus not be properly diagnosed
on clinical grounds (Krasnianski et al., 2006a, b)
Discussion
This multi-centre collaborative study analysed ﬁndings from MRI
scans in a large number of sCJD cases and controls; and has
provided evidence that justiﬁes the inclusion of deﬁned MRI
pattern in the clinical diagnostic criteria for sCJD. In a previous
manuscript, we reported characteristic MRI patterns for each
molecular CJD subtype (Meissner et al., 2009) and identiﬁed
variables which allowed for the best discrimination between
those subtypes. We chose the following radiological signs as
predictors of sCJD subtypes: high signal in (i) more than three
Table 6 Comparison of new and old criteria
n % Sensitivity Speciﬁcity
Current criteria
Deﬁnite sporadic CJD cases with both EEG and 14-3-3 tests performed
EEG atypical & 14-3-3 test negative 8 7.8
EEG typical & 14-3-3 test negative 7 6.8
EEG atypical & 14-3-3 test positive 49 47.6
EEG typical & 14-3-3 test positive 39 37.9 92.2
Total 103 100
Controls with both EEG and 14-3-3 tests performed
EEG atypical & 14-3-3 test negative 37 71.2 71.2
EEG typical & 14-3-3 test negative 1 1.9
EEG atypical & 14-3-3 test positive 12 23.1
EEG typical & 14-3-3 test positive 1 1.9
Total 52 100
New criteria
Deﬁnite sporadic CJD cases with all three tests performed (EEG, 14-3-3 tests, and MRI FLAIR and DWI, new criteria)
Current criteria negative & MRI negative 1 2.0
Current criteria positive & MRI negative 7 14
Current criteria negative & MRI positive 3 6
Current criteria positive & MRI positive 39 78 98
Total 50 100
Controls with all three tests performed (EEG, 14-3-3 tests, and MRI FLAIR and DWI)
Current criteria negative & MRI negative 17 70.8 70.8
Current criteria positive & MRI negative 5 20.8
Current criteria negative & MRI positive 1 4.2
Current criteria positive & MRI positive 1 4.2
Total 24 100
Table 7 Sensitivity of old and new criteria for each molecular disease subtype
Disease
subtype
Positive MRI/total
(%)
Positive 14-3-3/total
(%)
Positive EEG/total
(%)
New criteria positive
(%)
Old criteria
positive (%)
MM1 33/43 (76.7) 38/42 (90.5) 26/43 (60.5) 100 97.6
MM2 14/15 (93.3) 9/14 (64.3) 3/14 (21.4) 92.3 69.2
MV1 6/6 (100) 5/6 (83.3) 3/6 (50) 100 100
MV2 8/8 (100) 7/8 (87.5) 0/8 (0) 100 87.5
VV1 2/2 (100) 2/2 (100) 1/2 (50) 100 100
VV2 9/15(60) 14/15 (93.3) 0/15 (0) 100 93.3
All 72/89 (80.9) 75/87 (86.2) 33/88 (37.5) 98.8 91.9
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(iv) any thalamic nuclei; and (v) cerebellum. Multivariate analysis,
including the ﬁve selected regions, was performed in order to
allow independent assessment of these parameters and a speciﬁc
MRI lesion pattern for each molecular disease subtype was identi-
ﬁed (Meissner et al., 2009). Speciﬁcity of MRI changes was not
addressed. Since the information on speciﬁcity is essential for an
assessment of the true utility of MRI brain scan in the diagnosis of
sCJD, we performed the current study.
In order to assess the sensitivity of MRI in the diagnosis of sCJD,
we developed a set of variables which allowed the optimum dis-
crimination between CJD and controls. In this analysis, we selected
anatomical regions which have been demonstrated to be fre-
quently affected (Meissner et al., 2009). The characteristic MRI
lesion pattern, which allowed for the best discrimination between
sCJD cases and controls was found to be high signal intensity in
FLAIR or DWI in at least two cortical regions, or signal increase in
the caudate nucleus and putamen. Based on these ﬁndings, we
propose that the clinical diagnostic criteria for sCJD are amended
to include MRI signal abnormalities as deﬁned above (Fig. 1). The
MRI ﬁndings will thus be equivalent to elevated levels of 14-3-3
proteins or periodic sharp and slow wave complexes in the EEG for
the clinical diagnosis of probable sCJD.
With respect to current clinical tests for sCJD, the EEG was the
ﬁrst in vivo test to be used to support the clinical diagnosis of
sCJD. However, the EEG has been shown to be positive in only a
subset of sCJD patients, usually MM1 or MV1 cases. Typically,
periodic sharp wave complexes are detected late in the disease
and the median time to positive EGG is around 12 weeks. This
corresponds to the terminal stages of the illness (Poser et al.,
1999; Zerr et al., 2000a; Collins et al., 2006). A number of CSF
biomarkers have been reported in sCJD, including 14-3-3, tau,
S100b, neuron-speciﬁc enolase, phosphorylated tau and abeta,
with the majority of available data relating to 14-3-3 and tau
proteins (Sanchez-Juan et al., 2006). Both these biomarkers
support the clinical CJD diagnosis with a sensitivity of 92% and
speciﬁcity of 71% (Sanchez-Juan et al., 2006). However, a
number of publications have indicated that low levels of these
biomarkers are present in the CSF in some atypical CJD variants
(Castellani et al., 2004; Sanchez-Juan et al., 2006; Gmitterova ´
et al., 2008). Biological variables such as long disease duration,
young age at onset, type 2 pathogenic prion protein and hetero-
zygosity at codon 129 genotype of the PrP gene are all associated
with low biomarker levels (Parchi et al., 1999; Zerr et al., 2000b;
Castellani et al., 2004; Sanchez-Juan et al., 2006). This is in con-
trast with the results of MRI scans in some atypical and rare
variants of sCJD, such as VV1 and MV2: in VV1 patients there
is high signal in the cortical areas and normal signal in the basal
ganglia, while in MV2 patients characteristic abnormalities are
seen in the basal ganglia, putamen and thalamus (Meissner
et al., 2005; Krasnianski et al., 2006b, 2008). Characteristic
lesion patterns have recently been reported for patients with
other molecular disease subtypes (Meissner et al., 2009) and the
question was raised whether MRI brain scan might contribute to
the improved diagnosis across sCJD subtypes (Tschampa et al.,
2005; Meissner et al., 2009).
Table 7 shows the data on positive tests in a subgroup of
patients with known molecular type. MRI ﬁndings are positive in
81% of sCJD patients. Sensitivity of the 14-3-3 test is 86% and
signiﬁcantly less for the EEG. By combination of all parameters,
sensitivity is 98% and speciﬁcity of the criteria is 71%. Although
the frequency and location of high signal intensities vary between
subtypes, by amendment of clinical criteria, most molecular
disease subtypes will be covered, including rare subtypes VV1
and MV2 (Table 7).
Our results indicate a high rate of agreement between identiﬁ-
cation of cortical parietal, temporal and occipital signal and basal
ganglia involvement between ﬁve raters, even in a cohort of
patients where MRI scans were acquired at different centres,
with some modiﬁcations. These results suggest that MRI is a
robust investigation in sCJD and qualiﬁes as a potential biomarker
for CJD.
A limitation of this study is the high number of sCJD cases as
compared to controls. However, the gold standard for the valida-
tion of the clinical diagnostic criteria was the analysis of the subset
of sCJD cases in which the diagnosis had been conﬁrmed by
neuropathology. In controls, only data from patients in which
the diagnosis of CJD had been deﬁnitely excluded by neuropathol-
ogy or in which there was a deﬁnite alternative clinical diagnosis,
were used. This group included cases who recovered, cases with
inﬂammatory CSF ﬁndings indicating an alternative diagnosis or a
clinical course which excluded CJD as a diagnosis (Heinemann
et al., 2007). In the context of a multi-centre MRI study on a
rare disorder, achieving a high autopsy rate in non-cases is difﬁcult
and it would take many years to obtain a representative autopsy
sample of non-cases at a similar rate to the sCJD cases.
Epidemiological surveillance studies on rare disorders are person
and cost intensive and a study with selected MRI scans on more
than 300 cases and controls on a solely autoptic sample is unlikely
to be feasible in the near future. However, in this study, we have
achieved neuropathology conﬁrmation in 40% of controls and in
60% of CJD patients.
Our analysis has shown that MRI ﬁndings may lead to false
positive diagnosis in a small number of cases. This is an important
issue for the accurate diagnosis of sCJD. Almost 50% of false-
positive ﬁndings on the MRI were associated with inﬂammatory
conditions; the other diagnoses were Alzheimer’s disease and
Dementia with Lewy bodies (HaI ¨k et al., 2000; Tschampa et al.,
2001). Inﬂammatory conditions of the brain represent the most
important differential diagnosis as there may be a possibility for
treatment (Chang et al., 2007; Heinemann et al., 2007;
Geschwind et al., 2008). In our patients, diagnoses included
encephalitis of unknown origin and SREAT (Seipelt et al., 1999).
The latter diagnosis has been described previously as an important
treatable condition in the differential diagnosis of CJD. The crucial
question for the clinician is how to avoid the misinterpretation of
tests and how to avoid missing a treatable condition in a patient
with a rapid progressive dementia and focal neurological signs
(Josephs et al., 2009). Thorough analysis of the cerebrospinal
ﬂuid for routine parameters such as cell count, protein and oligo-
clonal bands (which are often positive in SREAT and other inﬂam-
matory conditions, but usually negative in CJD) may be helpful in
diagnosis (Jacobi et al., 2005; Green et al., 2007). As other tests,
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inﬂammatory conditions of the brain, accurate clinical diagnosis
can be a major challenge. Thus, patients with ‘inﬂammatory’
abnormalities in the CSF such as pleocytosis, high elevated protein
content and oligoclonal immunglobulin G should enter the
diagnostic pathway for potentially treatable conditions (Vernino
et al., 2007).
The time point at which the clinical diagnosis of sCJD is made
may be very important if treatment strategies become available as
any therapy will probably need to be started early if it is to be
effective. The EEG has been shown to become positive usually
only in the late stages of the disease. CSF biomarkers can
become positive in the early disease stages, as shown in a
cohort of patients with repeated lumbar punctures and multiple
CSF tests (Sanchez-Juan et al., 2007). With MRI the question on
when the typical changes appear is still unresolved because of the
limited number of patients with multiple scans. However, there is
a suggestion from the literature that MRI may become positive
early in the disease (Young et al., 2005; Fujita et al., 2008;
Galanaud et al., 2008; Hoshino et al., 2008). Further work will
be needed to address this question.
In summary, our data show that basal ganglia and cortical
hyperintensities represent the most frequent MRI ﬁndings in
sCJD and are present in most cases. Characteristic brain MRI
lesion patterns are helpful in establishing a diagnosis of sCJD
and may help to identify atypical sporadic disease forms. This is
the most comprehensive study on MRI ﬁndings in sCJD to date,
and in combination with previous studies, provides ﬁrm evidence
that brain MRI has a high sensitivity and speciﬁcity in the diag-
nosis of the disease.
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